Clinical ShowCase™: Developing a Personalized Treatment Plan for a Patient with Sickle Cell Disease

Release Date: July 27, 2021
Expiration Date: July 27, 2022

Activity Overview

This online activity is designed to provide concise and easy-to-digest education in an engaging and interactive case-based format. The case focuses on therapy aimed at reducing the frequency and severity of vaso-occlusive pain crises associated with sickle cell disease and well as monitoring for and detecting disease complications. The engaging format of this program includes interactive clinical decision points with explanations at the end of the activity, and an evidence-based review supporting the teaching points covered in the case.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Global Blood Therapeutics, Inc.

Target Audience

This educational activity is directed toward hematologist/oncologists, including pediatric hematologists, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with sickle cell disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess the role of disease-modifying therapies in sickle cell disease to develop individualized treatment plans
• Apply personalized treatment strategies to reduce or address complications associated with sickle cell disease

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Julie Kanter, MD
Director, Adult Sickle Cell Program
Associate Professor, Hematology-Oncology
University of Alabama
Birmingham, AL

Disclosures: Grant/Research Support: National Heart, Lung, and Blood Institute, Health Resources and Services Administration, Centers for Disease Control and Prevention; Consultant: Novartis Pharmaceuticals, Forma Therapeutics, Graphite Bio, Axcella Health, BPL; Other (Honoraria): GLG Pharma, Guidepoint Global, Medscape.

Foluso “Joy” Ogunsile, MD
Assistant Professor, Hematology-Oncology
University of Alabama
Birmingham, AL

Disclosures: Consultant: Forma Therapeutics, Global Blood Therapeutics, Novartis.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.